Sisram Medical Ltd. (1696) AI Stock Analysis

• Market Cap: HK$2.21B
• Dividend Yield: 2.72%
• Average Volume (3M): 850.73K
• Price to Earnings (P/E): 13.8
• Beta (1Y): 1.37
• Revenue Growth: -3.32%
• EPS Growth: -12.94%
• Country: HK
• Employees: 1,000
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): 0.11
• Shares Outstanding: 468,343,080
• 10 Day Avg. Volume: 552,975
• 30 Day Avg. Volume: 850,725
• PEG Ratio: -0.45
• Price to Book (P/B): 0.49
• Price to Sales (P/S): 0.65
• P/FCF Ratio: 7.50
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: HK$6.00
• Price Target Upside: 28.21% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 60 Neutral
• Price Target: HK$5.00 ▲(6.84% Upside)

Sisram Medical Ltd. has a stable financial foundation with strong profitability and low leverage, but faces challenges with declining revenue growth and negative free cash flow growth. Technical indicators suggest bearish momentum, which could impact short-term performance. The valuation is reasonable, with a fair P/E ratio and a decent dividend yield.

Sisram Medical Ltd. Business Overview & Revenue Model

Company Description

Sisram Medical Ltd. (1696) is a global leader in the field of aesthetic medicine, specializing in innovative technologies and solutions for non-invasive and minimally invasive procedures. The company operates primarily within the aesthetics sector, providing a wide range of advanced medical devices and products that enhance beauty and improve patient outcomes. Sisram Medical focuses on several core areas, including laser-based systems for skin rejuvenation, body contouring, and hair removal, as well as complementary products that support aesthetic treatments.

How the Company Makes Money

Sisram Medical generates revenue through the sale of its advanced medical devices and equipment to healthcare professionals, clinics, and aesthetic practices. The primary source of income stems from direct sales of its laser systems and technologies, which are often accompanied by consumables and accessories that are essential for their operation. Additionally, the company benefits from recurring revenue streams through service agreements, maintenance contracts, and the sale of consumable products associated with its devices. Strategic partnerships with distributors and collaborations with aesthetic practitioners further enhance its market reach and contribute to its earnings, allowing Sisram Medical to capitalize on the growing demand for aesthetic treatments worldwide.

Sisram Medical Ltd. Financial Statement Overview

Summary

Sisram Medical Ltd. demonstrates a stable financial position with strong profitability margins and low leverage. However, the significant decline in revenue growth and negative free cash flow growth are areas of concern that need to be addressed to ensure long-term sustainability.

Income Statement

Sisram Medical Ltd. shows a mixed performance in its income statement. The TTM data indicates a decline in revenue growth rate by 46.8%, which is concerning. However, the company maintains a strong gross profit margin of 62.1% and a net profit margin of 7.2%, indicating efficient cost management. The EBIT and EBITDA margins are moderate at 7.9% and 11.1%, respectively, suggesting stable operational efficiency despite revenue challenges.

Balance Sheet

The balance sheet of Sisram Medical Ltd. is relatively strong, with a low debt-to-equity ratio of 0.09, indicating low financial leverage and risk. The return on equity is modest at 4.4%, reflecting moderate profitability on shareholder investments. The equity ratio stands at 73.6%, showcasing a solid equity base relative to total assets, which enhances financial stability.

Cash Flow

The cash flow statement reveals some challenges, with a negative free cash flow growth rate of -18.6% in the TTM period. However, the company maintains a healthy free cash flow to net income ratio of 0.92, indicating good cash conversion. The operating cash flow to net income ratio is 0.35, suggesting adequate cash generation from operations relative to net income.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	345.86M	349.11M	359.29M	354.48M	294.29M	162.09M
Gross Profit	210.72M	216.68M	219.53M	202.23M	166.86M	90.30M
EBITDA	33.03M	38.91M	53.43M	58.38M	55.96M	28.19M
Net Income	20.60M	25.13M	31.50M	40.17M	31.25M	13.34M
Balance Sheet
Total Assets	633.26M	627.26M	613.50M	555.60M	530.13M	431.81M
Cash, Cash Equivalents and Short-Term Investments	62.01M	71.98M	70.60M	91.49M	157.96M	116.37M
Total Debt	46.97M	43.20M	44.68M	41.34M	41.62M	37.06M
Total Liabilities	145.56M	142.47M	143.98M	123.38M	126.51M	99.92M
Stockholders Equity	466.38M	464.03M	452.31M	430.87M	402.18M	331.89M
Cash Flow
Free Cash Flow	20.87M	30.38M	35.37M	-42.28M	29.41M	16.46M
Operating Cash Flow	24.23M	33.08M	43.94M	22.04M	32.38M	25.74M
Investing Cash Flow	-17.64M	-6.59M	-32.99M	-52.11M	-46.77M	-33.51M
Financing Cash Flow	-18.79M	-16.11M	-20.97M	-17.85M	55.78M	-12.21M

Sisram Medical Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 4.68
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1696, the sentiment is Negative. The current price of 4.68 is below the 20-day moving average (MA) of 5.21, below the 50-day MA of 5.69, and above the 200-day MA of 4.62, indicating a neutral trend. The MACD of -0.29 indicates Positive momentum. The RSI at 34.07 is Neutral, neither overbought nor oversold. The STOCH value of 11.13 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1696.

Sisram Medical Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
1789	69 Neutral	HK$6.17B	19.27	11.24%	1.19%	25.18%	55.79%
6669	67 Neutral	HK$4.11B	36.06	7.44%	―	12.94%	212.66%
1302	66 Neutral	HK$8.68B	112.92	1.98%	―	3.42%	-70.82%
1696	60 Neutral	HK$2.21B	13.78	4.46%	2.72%	-3.32%	-12.94%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
2235	42 Neutral	HK$2.99B	―	-1.39%	―	49.86%	80.35%
9996	41 Neutral	€4.09B	―	-11.20%	―	29.25%	9.02%

Sisram Medical Ltd. Corporate Events

Sisram Medical Enhances Market Position with New Distribution Agreement

Sisram Medical Ltd. announced a Commercial Distribution Co-operation Agreement with Fosun Wanbang (Jiangsu) to enhance the distribution of DAXXIFY® in Mainland China. This agreement aligns with Sisram’s business model, allowing the company to leverage its sublicense rights to improve its market position and generate additional revenue. The collaboration aims to streamline the supply chain, ensuring product safety and quality, while enhancing market efficiency.

The most recent analyst rating on (HK:1696) stock is a Buy with a HK$7.00 price target. To see the full list of analyst forecasts on Sisram Medical Ltd. stock, see the HK:1696 Stock Forecast page.

Sisram Medical Partners with Aesthetic Expert Nurse Jamie to Boost Global Reach

Sisram Medical Ltd announced a strategic collaboration between its subsidiary, Alma Lasers Ltd, and renowned skin-care expert Jamie Sherrill, known as Nurse Jamie. This partnership aims to enhance consumer engagement and strengthen Alma’s leadership in aesthetic technologies by leveraging Sherrill’s expertise and influence to promote Alma’s flagship platforms globally, potentially increasing demand and growth opportunities for clinic partners worldwide.

The most recent analyst rating on (HK:1696) stock is a Buy with a HK$6.50 price target. To see the full list of analyst forecasts on Sisram Medical Ltd. stock, see the HK:1696 Stock Forecast page.

Sisram Medical Launches Innovative PixelPeel™ Laser Treatment

Sisram Medical Ltd has announced the launch of PixelPeel™, a new laser peel treatment designed for effective skin renewal with minimal downtime. Debuting in North America, this treatment uses Alma’s MotionSync™ technology for precise and safe exfoliation, enhancing skin texture and tone. The introduction of PixelPeel™ is expected to expand the market for Sisram’s existing systems and accelerate the adoption of their devices globally.

The most recent analyst rating on (HK:1696) stock is a Buy with a HK$6.50 price target. To see the full list of analyst forecasts on Sisram Medical Ltd. stock, see the HK:1696 Stock Forecast page.

Sisram Medical Reports Mixed Interim Results for H1 2025

Sisram Medical Ltd announced its interim results for the first half of 2025, reporting a slight decline in revenue by 1.9% to US$165.5 million compared to the same period in 2024. Despite this, the APAC region showed strong performance with a 17.6% increase in revenue, and the injectables line saw a significant growth of 218.1%. However, the company’s gross profit margin decreased by 2.4 percentage points, and adjusted net profit fell by 28.1%. The board decided not to declare an interim dividend for this period.

The most recent analyst rating on (HK:1696) stock is a Buy with a HK$6.50 price target. To see the full list of analyst forecasts on Sisram Medical Ltd. stock, see the HK:1696 Stock Forecast page.

Sisram Medical Ltd. Declares Final Dividend for 2024

Sisram Medical Ltd. has announced a final cash dividend of HKD 0.126 per share for the fiscal year ending December 31, 2024. The dividend will be subject to a 20% withholding tax as per Israeli Tax Ordinance, with the payment date set for September 9, 2025. Shareholders have the option to apply for a reduced tax rate under applicable tax treaties, although no such treaty exists between Israel and Hong Kong. This announcement reflects the company’s commitment to returning value to its shareholders while navigating the complexities of international tax regulations.

Sisram Medical Ltd Announces 2024 Final Dividend and Tax Details

Sisram Medical Ltd has announced a final dividend of HK$0.126 per share for the year ending December 31, 2024, to be paid on or around September 9, 2025. Shareholders will be subject to a 20% withholding tax on the dividend, with provisions for reduced rates under applicable tax treaties, although no such treaty exists with Hong Kong.

Sisram Medical Ltd Schedules Board Meeting for Interim Results Review

Sisram Medical Ltd has announced that its board of directors will meet on August 20, 2025, to review and approve the interim results for the first half of the year ending June 30, 2025. The meeting will also consider the declaration of an interim dividend, which could impact the company’s financial distribution to shareholders.

Sisram Medical Advances DAXXIFY® Commercialization in China

Sisram Medical Ltd announced that the commercialization of its product, DAXXIFY® (DaxibotulinumtoxinA-lanm), in Mainland China is progressing steadily. The company is actively working on regulatory filings, market access, and building a professional team to support the product’s launch, expressing strong confidence in its market potential.